drugset
drugset / Trial / NCT03916419

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419 ↗

Phase 2 Completed 26 enrolled Washington University School of Medicine
Non-randomizedSequentialOpen-labelTreatment

Summary

Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.

Timeline

Start
2019-06-20
Primary completion
2025-09-28
Completion
2025-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin AUC Unknown 2 unknown Intravenous
Subject Durvalumab Monoclonal antibody 10 mg/kg —
Subject Paclitaxel Small molecule 50 mg/m2 Intravenous

Indications

non-small cell lung carcinoma